



*The Society for Healthcare
Epidemiology of America, Inc.*

November 5, 2001

Dear SHEA Member,

We are pleased to announce the formation of two new training opportunities for Infectious Diseases Fellows. The grants are co-sponsored by the Society for Healthcare Epidemiology of America (SHEA) with Ortho McNeil and GlaxoSmithKline. Both awards are for one fellow for two years in support of fellowship training and research activities in specific areas related to healthcare epidemiology.

- The SHEA/Ortho McNeil Fellowship in Antimicrobial Management is a two year award for \$30,000 per year. The successful applicant will be able to demonstrate a commitment to research in antimicrobial management. The proposed project would be expected to study novel and unique methods for improving the use of antimicrobial agents.
- The SHEA/GlaxoSmithKline Fellowship in Surgical Infections is a two year award for \$40,000 per year. Proposed projects are to focus on the prevention, control and surveillance of infections resulting from surgical procedures.

Institutional commitment to the Infectious Diseases Fellows' proposed project is important for the applicant to be successful. The application process will occur in two parts. The first part is a general application that is due by December 15, 2001. Applicants will be notified by January 1, 2002 whether or not they have been selected to submit the second part of the application; which is a detailed description of the proposed research project that is due by February 1, 2002. Awards are expected to be announced by March 15, 2002 and begin July 1, 2002.

Applications are available by contacting Leslie Thomas at SHEA (lthomas@talley.com). We look forward to working with you and your interested Infectious Diseases Fellows on these two new and exciting research opportunities.

Sincerely yours,


Annual Planning Meeting Committee, SHEA:

Trish M. Perl, MD, Msc
tperl@welchlink.welch.jhu.com

Rebecca Wurtz, MD
rwurtz@northwestern.edu

Louise-Marie Dembry, MD
dembry@ynhh.com

Tobi Karchmer, MD
tkarchmer@wfubmc.edu



BIOPATCH Antimicrobial Dressing

Nosocomial infections affect millions of patients annually and greatly increase treatment costs. BIOPATCH is the ONLY percutaneous device dressing that reduces nosocomial infection rates.

- Inhibits microbial population underneath by an average of 100 times as compared to skin under non-medicated patches
- Continually releases chlorhexidine gluconate for 7 days¹
- Broad-spectrum activity
- Absorbs eight times its own weight in fluid¹
- One inch zone of inhibition
- Non-toxic, non-irritating¹

Indications For Use:

- Central Venous Catheters (CVCs)
- Epidural analgesia catheters
- CAPD catheters
- Orthopedic pins

For use with vascular and non-vascular percutaneous devices. Vascular devices include IV catheters, peripherally inserted central catheters, central venous lines, arterial catheters, dialysis catheters and others. Non-vascular percutaneous devices include external fixator pins, peritoneal dialysis catheters and epidural catheters.

¹Shapiro JM, Bond EL, Garman JK. Use of chlorhexidine dressing to reduce microbial colonization of epidural catheter. *Anesthesiology*. 1990;73:625-631.

Capitalized product names are trademarks of ETHICON, INC.



Johnson & Johnson
ADVANCED WOUND CARE
a division of ETHICON, INC.

P.O. Box 151, Somerville, New Jersey 08876-0151
© ETHICON, INC. 2001